US tariffs will have minimal impact on Indian pharma service companies like CDMOs: Report
New Delhi [India], March 10 (ANI): Indian pharma companies like CDMOs (Contract Development and Manufacturing Organizations) will not see major disruptions from the proposed US tariffs of 10-25 per cent, according to a report by B&K Securities.
The report highlighted that Indian pharma services companies will continue to benefit from favourable global factors despite concerns over new trade restrictions.
<